ライフサイエンスコーパス: alanine aminotransferase

1 blood-fed Aedes aegypti mosquitoes requires alanine aminotransferase.

2 els of lactate dehydrogenase, aspartate, and alanine aminotransferase.

3 6, decreased glutathione, and elevated serum alanine aminotransferase.

4 ts with high viral load and normal levels of alanine aminotransferase.

5 rin, transferrin saturation, hemoglobin, and alanine aminotransferase.

6 danoprevir can lead to grade 4 increases in alanine aminotransferase.

7 on markers such as increased level of serum alanine aminotransferase.

8 els of lactate dehydrogenase, aspartate, and alanine aminotransferase.

9 tory cytokine concentration, cystatin C, and alanine aminotransferase.

10 l ventilation (OR 0.24), MELD (OR 0.93), and alanine aminotransferase (1.02) were the only significan

11 ]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib gr

12 ), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypo

13 verse events were increases in lipase (15%), alanine aminotransferase (12%), and aspartate aminotrans

14 atched cold-stored DCD livers regarding peak alanine-aminotransferase (1239 vs 2065 U/L, P = 0.02), i

15 roup versus the placebo group were increased alanine aminotransferase (146 [25%] of 573 patients vs s

16 nsferase, 168[166] vs. 57[67] IU/L; P=0.006; alanine aminotransferase, 151[197] vs. 58[103] IU/L; P=0

17 (affecting >/=2% of patients) were increased alanine aminotransferase (17 [3%] of 573 vs one [<1%] of

18 erse events were transaminase increases (40% alanine aminotransferase, 17% aspartate aminotransferase

19 ransferase, 22.67 U/L (19.94-25.41 U/L); for alanine aminotransferase, 21.77 U/L (18.96-24.59 U/L); f

20 dian values of total bilirubin (6.67 mg/dL), alanine aminotransferase (2288.82 U/L), aspartate aminot

21 on to continue the trial (relative change in alanine aminotransferase -24%, 95% CI -45 to -3).

22 g dose escalation included grade 3 increased alanine aminotransferase (240 mg daily) and grade 4 dysp

23 +/- 2.1 vs 36.0 +/- 9.3 mg/dL; p </= 0.001), alanine aminotransferase (266.5 +/- 295.2 vs 861.8 +/- 8

24 (27 [8%] patients vs 0 patients), increased alanine aminotransferase (29 [8%] vs six [2%]), herpes z

25 40 patients in the placebo group), increased alanine aminotransferase (32 [6%] vs four [<1%]), and hy

26 nsferase (32.4 +/- 17.4 vs 21.5 +/- 6.9U/L), alanine aminotransferase (39.9 +/- 28.6U/L vs 23.8 +/- 1

27 participants developed a transaminase rise (alanine aminotransferase 4.5-5.9 times the upper limit o

28 higher than that with placebo were increased alanine aminotransferase (40 [19%] of 216 patients in th

29 criteria, those with CFLD had higher median alanine aminotransferase (42 versus 27, P = 0.005), aspa

30 ubjects with a FibroScan >6.8 kPa had higher alanine aminotransferase (42 versus 28U/L, P = 0.02), AS

31 e aminotransferase (65 [26%]), and increased alanine aminotransferase (47 [19%]).

32 s 17 [2.6%] of 655), reversible increases in alanine aminotransferase (51 [7.8%] vs six [0.9%]), and

33 ad a higher incidence of increased levels of alanine aminotransferase (60%, vs. 43% with sunitinib).

34 uparlisib versus placebo group were elevated alanine aminotransferase (63 [22%] of 288 patients vs fo

35 rica were more likely to have elevated serum alanine aminotransferase (72% vs. 50%; P < 0.01) and hig

36 3-4 laboratory abnormalities were increased alanine aminotransferase (73 [30%] patients) and increas

37 Plasma alanine aminotransferase (78 U/L [range, 19-204] versus

38 Median peak levels were alanine aminotransferase 892 U/L, alkaline phosphatase 3

39 -type mice accompanied by elevated levels of alanine aminotransferase, a marker of liver injury.

40 roportion of patients with a 50% increase in alanine aminotransferase activity did not differ between

41 omes included a greater than 50% increase in alanine aminotransferase activity over the admission val

42 HFD also increased hepatic steatosis, plasma alanine aminotransferase activity, inflammation, oxidati

43 on liver mass, serum cholesterol, and serum alanine aminotransferase activity.

44 y mass and liver damage as measured by serum alanine aminotransferase activity.

45 e centrilobular necrosis and increased serum alanine aminotransferase activity.

46 y histology, propidium iodide injection, and alanine aminotransferase after IRI.

47 excess nitrogen, we investigated the role of alanine aminotransferase (ALAT) in blood-fed Aedes aegyp

48 In the SOS cohort, E167K carriers had higher alanine aminotransferase ALT and lower lipid levels (P <

49 r inhibitor-1 (markers for fibrinolysis) and alanine aminotransferase (ALT) (marker of ischemia-reper

50 retinol-binding protein by using ELISA, and alanine aminotransferase (ALT) activity by using a color

51 s the induction of immune tolerance, and the alanine aminotransferase (ALT) activity in these mice re

52 Elevated alanine aminotransferase (ALT) activity, an important ma

53 on and liver injury as demonstrated by lower alanine aminotransferase (ALT) activity, hepatocyte ball

54 ic ethanol, hepatic triglycerides and plasma alanine aminotransferase (ALT) and aspartate aminotransf

55 or allopurinol led to rapid normalization of alanine aminotransferase (ALT) and discontinuation of st

56 brosis significantly reduced serum levels of alanine aminotransferase (ALT) and liver steatosis and f

57 out the relationship between serum levels of alanine aminotransferase (ALT) and markers of atherogene

58 ecognition and at the time of peak levels of alanine aminotransferase (ALT) and total bilirubin (TBL)

59 nt predictor for incomplete normalization of alanine aminotransferase (ALT) at 6 months was age at pr

60 d were then monitored with serum HBV DNA and alanine aminotransferase (ALT) at least every 3 months.

61 At the end of the study, the alanine aminotransferase (ALT) concentration decreased i

62 ety outcomes were serious adverse events and alanine aminotransferase (ALT) concentrations over 12 we

63 Clinical implications of persistent alanine aminotransferase (ALT) elevation and associated

64 grade 4 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation with fevers, an

65 eek delay, persistent viremia accompanied by alanine aminotransferase (ALT) elevation, intrahepatic i

66 sis, neutrophilic infiltration, and >10-fold alanine aminotransferase (ALT) elevations.

67 Alanine aminotransferase (ALT) flares occur frequently d

68 th the occurrence of at least 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007

69 of the studies assessed associations between alanine aminotransferase (ALT) level and T2D, with heter

70 pulation was restricted to those with normal alanine aminotransferase (ALT) level at baseline.

71 trol mice Con A markedly increased the serum alanine aminotransferase (ALT) level in a dose-dependent

72 The initial alanine aminotransferase (ALT) level, the maximal ALT le

73 defined as viral DNA levels >2000 IU/mL and alanine aminotransferase (ALT) levels >80 U/mL, respecti

74 of pruritus, disappearance of jaundice, and alanine aminotransferase (ALT) levels <1.5 times the upp

75 her portal inflammation (2.4 versus 2.2) and alanine aminotransferase (ALT) levels (133 versus 105 U/

76 The TDF group had less incidence of maternal alanine aminotransferase (ALT) levels above two times th

77 liver fibrosis, inflammation, steatosis, and alanine aminotransferase (ALT) levels and viscoelastic a

78 ular injury is identified internationally by alanine aminotransferase (ALT) levels equal to or exceed

79 vestigated the frequency with which elevated alanine aminotransferase (ALT) levels were followed by d

80 erum insulin, fasting serum lipids and serum alanine aminotransferase (ALT) levels were measured and

81 Observational studies of the association of alanine aminotransferase (ALT) levels with ischaemic hea

82 t3L KO than in wildtype (WT) mice with lower alanine aminotransferase (ALT) levels, reduced hepatic n

83 rked by an elevation in the amount of plasma alanine aminotransferase (ALT) may be responsible for he

84 Alanine aminotransferase (ALT) predicts type 2 diabetes

85 index (APRI), fibrosis-4 index (FIB-4), AST/alanine aminotransferase (ALT) ratio (AAR), and age-plat

86 defined as a greater than 3-fold increase in alanine aminotransferase (ALT) that exceeded 100 IU/L.

87 CatD and alanine aminotransferase (ALT) were measured in plasma.

88 43.9% had HBV DNA>/=20,000 IU/mL, and 26.7% alanine aminotransferase (ALT)>/=2x upper limit of norma

89 aspartate aminotransferase, alanine aminotransferase (ALT), acute kidney injury (AKI

90 crease in aspartate aminotransferase, (AST), alanine aminotransferase (ALT), alkaline phosphatase (AL

91 ate the causal effects of the liver enzymes, alanine aminotransferase (ALT), alkaline phosphatase (AL

92 YCHT treatment substantially reduced serum alanine aminotransferase (ALT), alkaline phosphatase (AS

93 n age; levels of aspartate aminotransferase, alanine aminotransferase (ALT), alkaline phosphatase, to

94 including gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotrans

95 the dramatic rise in the standard biomarker, alanine aminotransferase (ALT), and these miRNAs also re

96 levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total alkaline phosp

97 ion between cholesterol precursors and serum alanine aminotransferase (ALT), as a marker of liver dis

98 Alanine aminotransferase (ALT), aspartate aminotransfera

99 Serum levels of alanine aminotransferase (ALT), aspartate aminotransfera

100 pathological changes and increases in serum alanine aminotransferase (ALT), aspartate aminotransfera

101 Alanine aminotransferase (ALT), aspartate aminotransfera

102 athological analysis, apoptotic death, serum alanine aminotransferase (ALT), fluorescent-activated ce

103 Alanine aminotransferase (ALT), gamma-glutamyltransferas

104 14 days thereafter by assessing liver mass, alanine aminotransferase (ALT), mRNA expression, and his

105 Ag) serostatus, serum levels of HBV DNA, and alanine aminotransferase (ALT), quantitative serum HBsAg

106 risingly lower levels of steatosis and serum alanine aminotransferase (ALT).

107 iopsies, and laboratory values such as serum alanine aminotransferase (ALT).

108 damage, high aspartate (AST, >49.9 IU/L) and alanine aminotransferase (ALT, >56.1 IU/L), to the relat

109 idence interval [CI]: 1.72-3.36; P < 0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12-1.

110 aspartate aminotransferase (AST; p<0.0001), alanine aminotransferase (ALT; p<0.0001), conjugated bil

111 cid (BA) (>6 mumol/l) and elevation of serum alanine aminotransferases (ALT) (>45 U/l).

112 Also, we assessed serum levels of alanine-aminotransferase (ALT), liver histology, hepatic

113 steine treatment beyond the standard course (alanine aminotransferase [ALT] activity >100 U/L).

114 ects were classified as presumed NAFLD (pNF; alanine aminotransferase [ALT] level >/= 20 for women or

115 erases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) are usually increased in

116 alculated as (age x AST)/(platelet x radical alanine aminotransferase [ALT]).

117 plasma bilirubin (daily) and liver enzymes (alanine aminotransferase [ALT], aspartate aminotransfera

118 FIB-4, an index from serum fibrosis markers (alanine aminotransferase [ALT], AST, and platelets plus

119 hepatitis B virus [HBV] DNA: 6.0 log cp/mL; alanine aminotransferase [ALT]: 136 IU/L; 42% with cirrh

120 pase (three [1%] of 268 patients), increased alanine aminotransferase, anaemia, and fatigue (two [1%]

121 Chronic Hepatitis Cohort Study, 78% had >/=1 alanine aminotransferase and 37% had >/=1 hepatitis B vi

122 s B surface antigen, and 97% of patients had alanine aminotransferase and 44% had hepatitis B virus D

123 seen by decreases of 53% (p < 0.05) in serum alanine aminotransferase and 74% (p < 0.05) in hepatic t

124 ncreases in liver and serum BA levels, serum alanine aminotransferase and aspartate aminotransferase

125 ferences in histologic response rates, serum alanine aminotransferase and aspartate aminotransferase

126 cts with metabolic syndrome and/or levels of alanine aminotransferase and aspartate aminotransferase

127 ely not to respond to UDCA therapy, based on alanine aminotransferase and aspartate aminotransferase

128 e or increase in their body weight and serum alanine aminotransferase and aspartate aminotransferase

129 of balloon degeneration, and elevated serum alanine aminotransferase and aspartate aminotransferase

130 with 200 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase)

131 rum of Sirt1LKO mice had increased levels of alanine aminotransferase and aspartate aminotransferase.

132 concentrations in liver; and serum levels of alanine aminotransferase and aspartate aminotransferase.

133 demonstrated 40% and 45% decrease in plasma alanine aminotransferase and BA levels, respectively.

134 verity of NAFLD was associated with level of alanine aminotransferase and cardiometabolic risk factor

135 ng body weight, blood cell counts, and serum alanine aminotransferase and creatinine.

136 s in levels of gamma-glutamyltransferase and alanine aminotransferase and dose-related weight loss.

137 In contrast, elevated alanine aminotransferase and gamma glutamyltransferase a

138 ndex > 40), in combination with elevation of alanine aminotransferase and gamma-glutamyl transferase,

139 as indicated by lower levels of TCDD-induced alanine aminotransferase and hepatic triglycerides.

140 played much less damage as assessed by serum alanine aminotransferase and histology.

141 , the most common of which were increases in alanine aminotransferase and in aspartate aminotransfera

142 Serum levels of alanine aminotransferase and interleukin (IL)-6 were sig

143 Serum alanine aminotransferase and interleukin-6 levels were l

144 ling (TUNEL) staining, circulating levels of alanine aminotransferase and lactate dehydrogenase, and

145 onditioning each significantly reduced serum alanine aminotransferase and liver mRNA expression of tu

146 attenuated APAP-induced serum elevations of alanine aminotransferase and microRNA-122 and completely

147 No patients had elevations in alanine aminotransferase and no patients prematurely dis

148 e 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipas

149 trong positive associations between elevated alanine aminotransferase and pretreatment IP-10 and betw

150 Median alanine aminotransferase and serum HBV DNA levels were 2

151 ow platelet counts, and high serum levels of alanine aminotransferase and total bilirubin at presenta

152 Serum levels of alanine aminotransferase and tumor necrosis factor-alpha

153 ine phosphatase, aspartate aminotransferase, alanine aminotransferase) and areas of liver parenchymal

154 atio, bilirubin, aspartate aminotransferase, alanine aminotransferase) and liver histology (hematoxyl

155 duced hepatic neutrophil accumulation, serum alanine aminotransferase, and attenuated liver injury af

156 , when compared to levels of HBV DNA, HBsAg, alanine aminotransferase, and HBV genotype, age, and sex

157 creased necrosis, infiltrating CD8(+) cells, alanine aminotransferase, and proinflammatory cytokines.

158 nfection, high viral loads, normal levels of alanine aminotransferase, and therapy with the combinati

159 anaemia, dyspnoea, hyponatraemia, increased alanine aminotransferase, and thrombocytopenia (three [1

160 patocellular injury glutamate dehydrogenase, alanine aminotransferase, aspartate aminotransferase (AS

161 ts with type 2 diabetes and nephropathy with alanine aminotransferase, aspartate aminotransferase (AS

162 tation significantly reduced plasma glucose, alanine aminotransferase, aspartate aminotransferase, AG

163 virus-infected patients was the elevation in alanine aminotransferase, aspartate aminotransferase, al

164 included neutropenia (14.5%) and reversible alanine aminotransferase/aspartate aminotransferase elev

165 ides, gamma-glutamyl transpeptidase, maximum alanine aminotransferase/aspartate aminotransferase, and

166 iated with lower serum alkaline phosphatase; alanine aminotransferase; aspartate aminotransferase; ga

167 tween biopsies, elevated serum aspartate and alanine aminotransferase (AST, ALT) (aOR AST: 3.34, ALT:

168 (ie, liver fat, hepatic de novo lipogenesis, alanine aminotransferase, AST, and gamma-glutamyl transp

169 A planned interim analysis of change in alanine aminotransferase at 24 weeks undertaken before e

170 ly to be IL28B non-CC, and had a lower serum alanine aminotransferase at baseline than non-black pati

171 % CI 0.005-0.49; P = 0.01), normal levels of alanine aminotransferase at the end of intervention (OR

172 ansferase (beta = 2.60; 95% CI: 0.99, 4.20), alanine aminotransferase (beta = 3.70; 95% CI: 1.78, 5.6

173 systemic injury, and mortality but not serum alanine aminotransferase, bilirubin, or amylase.

174 ripts, including XDH1, glutamine synthetase, alanine aminotransferase, catalase, superoxide dismutase

175 iation] serum aspartate aminotransferase and alanine aminotransferase compared to group B (aspartate

176 steatosis, inflammation, and serum levels of alanine aminotransferase compared with mice given a cont

177 s of ALP, gamma-glutamyl transpeptidase, and alanine aminotransferase, compared with placebo, in pati

178 %), elevated lipase level (15; 5%), elevated alanine aminotransferase concentration (12; 4%), and abd

179 s), increased aspartate aminotransferase and alanine aminotransferase concentration (14 [38%] patient

180 events in the ceritinib group were increased alanine aminotransferase concentration (24 [21%] of 115

181 k A allele had an increase in the mean serum alanine aminotransferase concentration of 5.2 IU/L, as c

182 rs780094 TT genotype had a higher mean serum alanine aminotransferase concentration than did those wi

183 One patient was ineligible (alanine aminotransferase concentration was above the req

184 Increased alanine aminotransferase concentrations caused two (3%)

185 DNA concentrations of >20 000 IU/mL), serum alanine aminotransferase concentrations of greater than

186 iver diseases, aspartate aminotransferase or alanine aminotransferase concentrations of more than two

187 Elevations of aspartate and alanine aminotransferase concentrations of three or more

188 ons in plasma aspartate aminotransferase and alanine aminotransferase concentrations; hepatic steatos

189 f leukopenia, thrombocytopenia, and elevated alanine aminotransferase, creatinine kinase, C-reactive

190 values (albumin, aspartate aminotransferase, alanine aminotransferase, creatinine, and cholesterol) w

191 a and of serum soluble NOX2-derived peptide, alanine aminotransferase, Cytokeratin-18 and homeostasis

192 crease in the group given placebo; levels of alanine aminotransferase decreased 21%-35% on average am

193 Alanine aminotransferase elevation TEAEs occurred in 17%

194 e observed, including 1 case of asymptomatic alanine aminotransferase elevation.

195 V reactivation in this cohort exhibited peak alanine aminotransferase elevations >2 times the upper l

196 Limited, asymptomatic, and transient alanine aminotransferase elevations in the low-dose (n =

197 Treatment-emergent grade 3 or 4 alanine aminotransferase elevations were observed in 4 p

198 eatment discontinuation, including 2 grade 4 alanine aminotransferase elevations.

199 FLD was associated with increasing levels of alanine aminotransferase, fasting glucose level, hyperte

200 ]), thrombocytopenia (five [28%]), increased alanine aminotransferase (five [28%]), and hypokalaemia

201 eatine phosphokinase (seven [8%]), increased alanine aminotransferase (five [6%]), and increased aspa

202 Alanine aminotransferase flares were observed in 17.1% o

203 should be followed up on a monthly basis for alanine aminotransferase followed by quantitative HBV DN

204 mon serious adverse event was an increase in alanine aminotransferase (four [2%] and five [2%] vs thr

205 rom 49.3 +/- 8.2 to 37.4 +/- 7) and level of alanine aminotransferase (from 52.1 +/- 25.7 IU/L to 25.

206 treatment decreased plasma concentrations of alanine aminotransferase, gamma-glutamyl transpeptidase,

207 dverse events (aspartate aminotransferase or alanine aminotransferase > 400; acetaminophen 9.5% vs pl

208 r IRI was assessed by histological analysis, alanine aminotransferase, hepatic neutrophil activation

209 besity (OffOb-OD), as demonstrated by raised alanine aminotransferase, hepatic triglycerides, and hep

210 cell count (HR 2.45, p 0.011), raised serum alanine aminotransferase (HR 4.22, p 0.016), raised seru

211 e in 82%, aspartate aminotransferase in 70%, alanine aminotransferase in 54%, and creatinine kinase i

212 We also measured levels of TNF and alanine aminotransferase in serum from mice.

213 Patients with elevated alanine aminotransferase in specialty care were more lik

214 elevation in four (15%) patients, increased alanine aminotransferase in two (8%) patients, increased

215 occurring in more than two patients included alanine aminotransferase increase (five [14%]), pyrexia

216 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase (four [11%]), hyperten

217 uzumab), fatigue (three [1%] vs seven [3%]), alanine aminotransferase increase (three [1%] vs four [2

218 y quantitative HBV DNA testing in those with alanine aminotransferase increase.

219 The most common adverse events were alanine aminotransferase increases (32 [8%] of 385 patie

220 loped fully reversible, asymptomatic grade 3 alanine aminotransferase increases (one on 50 mg, two on

221 were anxiety, dizziness, dyspnoea, increased alanine aminotransferase, influenza, insomnia and periph

222 an injury as determined by serum creatinine, alanine aminotransferase, lactate dehydrogenase, and cre

223 ed-chain amino acid/tyrosine ratio (BTR) <5, alanine aminotransferase level >/=42 IU/l, and AT VO(2)

224 female sex (P = .028), older age (P = .018), alanine aminotransferase level >1000 U/L (P = .027), tot

225 Elevations in the alanine aminotransferase level (to >3 times the upper li

226 histology, diabetes, sex, age, and change in alanine aminotransferase level and change in FIB-4 index

227 2,000 IU/ml and age >/= 40 years or elevated alanine aminotransferase level between 1-2 times the upp

228 1 incident each of grade 4 adverse events of alanine aminotransferase level elevation and rectal hemo

229 h a T allele in the IL28B gene, an increased alanine aminotransferase level in treatment-naive but no

230 adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper li

231 A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range

232 At 20 weeks, the alanine aminotransferase level was normal in 11 of 36 pa

233 e primary end point was normalization of the alanine aminotransferase level.

234 e start of the immune-clearance phase (serum alanine aminotransferase levels > 30 IU/l) before the ag

235 ith hepatitis C virus, persons with elevated alanine aminotransferase levels (>/=19 IU/L for women an

236 5 birth cohort (4.4 [3.8-5.1]), and elevated alanine aminotransferase levels (4.8 [4.2-5.6]) as indep

237 diarrhoea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).

238 ot induce liver pathology, assessed by serum alanine aminotransferase levels and histology.

239 ophylactic IL-22 significantly reduced serum alanine aminotransferase levels and histopathologic dama

240 on accompanied by a significant reduction of alanine aminotransferase levels and of proinflammatory c

241 33 resulted in a great decrease in the serum alanine aminotransferase levels and the number of Counci

242 Increasing age (>40 years), male sex, alanine aminotransferase levels and visceral adipose tis

243 s from IRI, as evidenced by diminished serum alanine aminotransferase levels and well-preserved tissu

244 Abnormal alanine aminotransferase levels at admission can indicat

245 African Americans (all P < 0.05), with high alanine aminotransferase levels in Hispanics (P < 0.05)

246 Liver injuries, as determined by alanine aminotransferase levels in plasma, were increase

247 Alanine aminotransferase levels increased in ALGS after

248 Four of the 6 patients (67%) had increased alanine aminotransferase levels of more than 1.5 times t

249 while 4 of 22 patients (18%) with increased alanine aminotransferase levels showed positive reactivi

250 orrelation with the NAFLD activity score and alanine aminotransferase levels than with steatosis alon

251 These changes and increased serum alanine aminotransferase levels were all mitigated in se

252 trongly increased in Hrn mice, whereas serum alanine aminotransferase levels were decreased.

253 rm, difference = 20.2%, 95% CI: 10.7, 30.5), alanine aminotransferase levels, and aspartate transamin

254 Notably, increases in alanine aminotransferase levels, apoptotic markers, and

255 Liver inflammation, alanine aminotransferase levels, chemokine (C-X-C) ligan

256 Five (42%) patients had raised alanine aminotransferase levels, four (33%) had raised a

257 nt liver injury dramatically decreased serum alanine aminotransferase levels, histological injury, th

258 o older ages as reflected by increased serum alanine aminotransferase levels, positive terminal deoxy

259 ge was assessed by hematoxylin and eosin and alanine aminotransferase levels.

260 s mirrored by significantly increased plasma alanine aminotransferase levels.

261 nt amelioration of ferritin, fibrinogen, and alanine aminotransferase levels.

262 ure cytokines and a marker of liver failure (alanine aminotransferase); liver tissues were collected

263 et NAFLD nor in 100 healthy individuals with alanine aminotransferase <22/20 IU/mL.

264 X-82 including leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and

265 , fall (three [2%] vs eight [6%]), increased alanine aminotransferase (nine [6%] vs none), and benign

266 tiviral therapy compared to placebo improved alanine aminotransferase normalization (risk ratio [RR]

267 g seroconversion (RR = 2.1, 95% CI 1.3-3.5), alanine aminotransferase normalization (RR = 1.4, 95% CI

268 improve HBV DNA suppression and frequency of alanine aminotransferase normalization and HBeAg serocon

269 cantly declined upon viremia suppression and alanine aminotransferase normalization induced by NUC th

270 odel including weight loss, type 2 diabetes, alanine aminotransferase normalization, age, and a nonal

271 7.9%, P<0.0001; bilirubin of 50.0%, P<0.001; alanine aminotransferase of 63.9%, P<0.005; and aspartat

272 ty endpoint was incidence of hepatotoxicity: alanine aminotransferase of greater than five times the

273 lobin (45 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (

274 pper limit of normal (ULN) or Hy's criteria (alanine aminotransferase or aspartate aminotransferase g

275 creased levels of blood lactate (P = 0.007), alanine aminotransferase (P = 0.027), bilirubin (P = 0.0

276 016) and higher celiac antibody (p < 0.001), alanine aminotransferase (p = 0.035) and thyroid-stimula

277 A risk score according to age, sex, alanine aminotransferase, previous chronic liver disease

278 reased aspartate aminotransferase, increased alanine aminotransferase, rash, and dyspnoea being the m

279 er AUROC than the aspartate aminotransferase-alanine aminotransferase ratio for identifying fibrosis

280 showing increased aspartate aminotransferase-alanine aminotransferase ratios, but, to date, has not b

281 d secondary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 +/- 88 U/L vs 8

282 itis B surface antigen (HBsAg), HBV DNA, and alanine aminotransferase results obtained while on DAA t

283 ood count, serum chemistry profile, level of alanine aminotransferase, rheumatoid factor activity, C4

284 nst liver IRI, evidenced by diminished serum alanine aminotransferase (sALT) levels and well-preserve

285 lcohol drinking, cigarette smoking, elevated alanine aminotransferase, serum hepatitis B surface anti

286 -adjusted analyses (age, sex, smoking, serum alanine aminotransferase, serum hepatitis B surface anti

287 itis (12 [13%] of 94 patients) and increased alanine aminotransferase (ten [11%]) in the combination

288 Liver injury was defined based on levels of alanine aminotransferase that were more than 3-fold the

289 seline and hepatitis flare as an increase in alanine aminotransferase to >/=3 times the upper limit o

290 Mean aspartate aminotransferase, alanine aminotransferase, total bilirubin, and gamma glu

291 tions in serum by >98%, and decreased plasma alanine aminotransferase, total bilirubin, and serum alk

292 and no relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin

293 ded higher AST (OR = 1.08, P = 0.007), lower alanine aminotransferase value (OR = 0.91, P = 0.002), a

294 positive for HBeAg and had normal levels of alanine aminotransferase were randomly assigned to group

295 inotransferases showed that the SDAP-ATs and alanine aminotransferases were exceptionally redundant,

296 ow neutrophil counts and increased levels of alanine aminotransferase, were more common among partici

297 that facilitates the breakdown of alanine by alanine aminotransferase when reoxygenation occurs.

298 group) had reversible, grade 4 increases in alanine aminotransferase, which led to early discontinua

299 lirubin, international normalized ratio, and alanine aminotransferase within 3 days posttransplant.

300 MC-2 in HS also decreased levels of alanine aminotransferase, zonula occludens-1, and interl